Collaboration with Eurofins Discovery
24 August 2021
Fusion Antibodies plc (AIM: FAB), a specialist in the pre-clinical
antibody discovery, engineering and supply for both therapeutic drug and
diagnostic applications, announces that is has entered into a commercial
collaboration agreement (the “Collaboration”)
with Eurofins Discovery (“Eurofins”), a leading provider of products and
services to the drug discovery industry. Eurofins is a Eurofins
Scientific SE (EUFI.PA) group company. Pursuant to the Collaboration,
Fusion will provide comprehensive
pre-clinical antibody development services from discovery, engineering,
and critical reagent supply to Eurofins and onwards to their customers.
The Collaboration is not expected to have a material impact on the
Company’s earnings in the current financial year, however, the Directors
of Fusion consider that it demonstrates a commitment by both parties to
provide world-class scientific expertise,
next-generation technology, and guidance to accelerate the delivery of
the best possible antibody against a broad range of targets and
therapeutic areas into the clinic for both parties.
As leading global innovation-driven and customer-focused providers of
antibody development services, Fusion Antibodies and Eurofins Discovery
share common values in the culture of collaboration and the pursuit of
scientific excellence.
Richard Jones, CEO of Fusion Antibodies commented: “We’re delighted to enter into this commercial collaboration with Eurofins which leverages the respective expertise of both partners, delivering on both our strategic objectives as well as providing a full client service package.”
Enquiries:
| Fusion Antibodies plc | www.fusionantibodies.com | |
| Richard Jones, Chief Executive Officer James Fair, Chief Financial Officer |
Via Walbrook PR | |
| Allenby Capital Limited | Tel: +44 (0)20 3328 5656 | |
| James Reeve (Corporate Finance) Tony Quirke (Sales and Corporate Broking) |
||
| Walbrook PR | Tel: +44 (0)20 7933 8780 fusion@walbrookpr.com | |
| Anna Dunphy | Mob: +44 (0)7876 741 001 | |
| Paul McManus | Mob: +44 (0)7980 541 893 | |
About Fusion Antibodies plc
Fusion is a Belfast based contract research organisation ("CRO")
providing a range of antibody engineering services for the development
of antibodies for both therapeutic drug and diagnostic applications.
The Company's ordinary shares were admitted to trading on AIM on 18
December 2017. Fusion provides a broad range of services in antibody
generation, development, production, characterisation and optimisation.
These services include antigen expression,
antibody production, purification and sequencing, antibody humanisation
using Fusion's proprietary CDRx TM platform
and the production of antibody generating stable cell lines to
provide material for use in clinical trials.
Since 2012, the Company has successfully sequenced and expressed
over 250 antibodies and successfully completed over 200 humanisation
projects and has an international, blue-chip client base, which has
included eight of the top 10 global pharmaceutical
companies by revenue.
The Company was established in 2001 as a spin out from Queen's University
Belfast. The Company's mission is to enable pharmaceutical and
diagnostic companies to develop innovative products in a timely and
cost-effective manner for the benefit of the global
healthcare industry. Fusion Antibodies provides a broad range of
services in antibody generation, development, production,
characterisation and optimisation.
Fusion Antibodies growth strategy is based on combining the latest
technological advances with cutting edge science to deliver new
platforms that will enable Pharma and Biotech companies get to the
clinic faster, with the optimal drug candidate and ultimately
speed up the drug development process.
The global monoclonal antibody therapeutics market was valued at $135.4
billion in 2018 and is forecast to surpass $212.6 billion in 2022, an
increase at a CAGR of 12.0 per cent. for the period 2018 to 2022. In
2017, seven of the world's ten top selling
drugs were antibody-based therapeutics with the combined annual sales of
these drugs exceeding $63.2 billion.
About Reach announcements
This is a Reach announcement. Reach is an investor communication service
aimed at assisting listed and unlisted (including AIM quoted) companies
to distribute media only / non-regulatory news releases into the public
domain. Information required to be
notified under the AIM Rules for Companies, UK MAR or other regulation
would be disseminated as an RNS regulatory announcement and not on
Reach.
